Abstract 148P
Background
To investigate the mean hemoglobin volume (MCV) in predicting the prognosis of residual gastric cancer (RGC).
Methods
A total of 225 RGC patients who underwent R0 resection in three hospitals in China from January 2003 to June 2015 were enrolled. The 3-year survival time were compared. Two-step regression was performed to analyze the effect of MCV on prognosis in RGC patients.
Results
A total of 208 patients were included in the final analysis, including 135 in Group L (MCV < 100 fl) and 73 in Group N (100 ≤ MCV < 120 fl). In different hospitals, there were different RGC occurrence times and initial gastric surgery intervals and different initial surgical reconstruction methods, the MCV value was not significantly correlated with hemoglobin content (R2=0.397). Comparing the 3 years overall survival time (OS) and disease-free survival time (DFS) with Group L, Group N patients were all better (P < 0.001). The stratified analysis showed that for stage III, with no anemia or mild anemia and chemotherapy, Group N patients had significantly better OS and DFS than the Group L patients (P < 0.05). Two-step multivariate analysis showed that MCV was an independent factor for the OS and DFS, and both the OS and DFS decreased as the MCV decreased (P<0.001).
Conclusions
MCV showed significant heterogeneity in patients with different RGC. Patients with low MCV have a significantly poor prognosis, and the MCV can therefore be a simple and effective indicator for assessing the prognosis of patients with RGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session